What is Zacks Research’s Forecast for LEXX FY2028 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Research issued their FY2028 earnings per share estimates for shares of Lexaria Bioscience in a research note issued to investors on Tuesday, February 10th. Zacks Research analyst J. Vandermosten expects that the company will post earnings of ($0.28) per share for the year. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share.

Several other equities research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lexaria Bioscience in a research note on Monday, December 29th. HC Wainwright decreased their price objective on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating for the company in a report on Friday, December 26th. Finally, Wall Street Zen lowered Lexaria Bioscience from a “hold” rating to a “sell” rating in a report on Sunday, December 7th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lexaria Bioscience presently has a consensus rating of “Hold” and an average target price of $1.50.

Lexaria Bioscience Stock Down 1.3%

Shares of LEXX stock opened at $0.68 on Wednesday. Lexaria Bioscience has a 12 month low of $0.46 and a 12 month high of $1.90. The company’s fifty day simple moving average is $0.78 and its 200-day simple moving average is $0.92. The firm has a market cap of $16.97 million, a PE ratio of -1.22 and a beta of 0.56.

Lexaria Bioscience (NASDAQ:LEXX) last issued its quarterly earnings results on Tuesday, January 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. Lexaria Bioscience had a negative net margin of 1,685.84% and a negative return on equity of 226.58%. The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.14 million.

Institutional Investors Weigh In On Lexaria Bioscience

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Lexaria Bioscience by 25.7% in the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock valued at $136,000 after purchasing an additional 44,939 shares during the last quarter. Byrne Asset Management LLC increased its stake in shares of Lexaria Bioscience by 236.8% during the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after purchasing an additional 74,180 shares during the period. Finally, Virtu Financial LLC bought a new stake in Lexaria Bioscience in the 3rd quarter valued at $28,000. Institutional investors own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.